

PRESS RELEASE

For release on January 8

The Efor Group acquires PharmEng Technology and becomes a global player in life sciences consulting, now present in 12 countries.

With an expanded presence across Europe, North America, and Asia, this alliance unlocks new opportunities to support industry players by combining specialized local expertise with global capabilities

Lyon (France), January 8, 2025 – Efor, leading European consultancy specializing in the pharmaceutical, biotechnology, and medical device industries, supported by Raise, Andera Acto, and Capza, today announces the acquisition of PharmEng Technology, a Canadian company recognized for its expertise in validation, quality assurance, regulatory affairs, vigilance, and engineering.



A Key Step Towards Achieving Global Leadership Status

This alliance with PharmEng Technology marks a decisive step in Efor's strategy to become a global leader in life sciences consulting by 2028, perfectly aligning with the trajectory defined during the second LBO in 2023.

Efor thus strengthens its activities in commissioning, qualification and validation, quality assurance, regulatory affairs, and engineering. The combined expertise and skills of the two groups will enable clients to benefit from comprehensive and integrated solutions on a global scale.

Furthermore, by joining forces with the PharmEng Technology teams, Efor enhances its presence in the United States while establishing a footprint in 8 additional regions: Canada, Brazil, Ireland, Denmark, Spain, Singapore, Malaysia, and Indonesia.

The consolidated group, comprising 2,800 employees, is now present in 12 countries, with an enhanced capacity to support large-scale international projects.



Meeting the Needs of a Rapidly Changing Market

In a sector where the demands of pharmaceutical, medtech, and biotechnology industries are constantly evolving, having a partner capable of combining local presence with global capacity is essential. Companies in the sector increasingly seek solutions that blend a deep understanding of regional regulatory expectations with technical and methodological expertise to stay ahead of trends and drive innovation.

With this acquisition, the group thus strengthens its ability to support the entire lifecycle of healthcare products, particularly in large-scale multinational projects.



"This union with PharmEng Technology is part of our ambition to become a global leader in our market by 2028 and represents a major step," says Mathieu ROGER, president and founder of the Efor Group. *"With over 25 years of existence, PharmEng Technology provides a strategic presence that strengthens our position in key geographies like the United States, while opening new markets for us in Canada, Brazil, Ireland, Denmark, Spain, Singapore, Malaysia, and Indonesia.*

Their recognized expertise and collaboration with leading international clients enhance our ability to deliver large-scale global projects.

This acquisition fully reflects our ambition: to combine strategic complementarity with scientific excellence in order to address the challenges faced by life sciences industries.

I would also like to thank our partners Raise, Andera Acto, and Capza for their support in this important step."

Shared Values in the Service of Excellence


Founded in 1997, PharmEng Technology quickly distinguished itself through its expertise and commitment to international clients. Its know-how and values of excellence, perfectly aligned with those of the Efor Group, reflect a shared commitment to building this large-scale industrial project to create a global leader in specialized healthcare consulting.



Alan KWONG, founder of PharmEng Technology *"Efor shares our values, our vision, and our commitment to our employees and clients. After nearly two years of successful collaboration, this alliance is a natural step. It allows us to expand our activities in Europe with Efor's strong positioning, while capitalizing on genuine complementary commercial and operational synergies. Together, as a global leader in life sciences expertise, we will be better positioned to meet the needs of our global clients in America, Asia, and Europe."*

About the Efor Group

Founded in 2013, the Efor Group has become one of the European leaders in life sciences consulting. Comprising a team of 2,500 employees across four countries (France, Belgium, Switzerland, and the United States) and generating a revenue of 240 million euros in 2024, the group offers a comprehensive range of services, from R&D to vigilance, to support its clients throughout the entire lifecycle of healthcare products.



About PharmEng Technology

Founded in 1997, PharmEng Technology is a consulting firm specializing in the pharmaceutical and biotechnology industries, with over 300 employees. Present in 12 countries across North America, South America, Asia, and Europe, PharmEng Technology supports its clients in the development and commercialization of their healthcare products, ensuring compliance with international regulatory standards.



Press contact

Floriane CARRET

